Leerink Partnrs Brokers Raise Earnings Estimates for ELAN

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities researchers at Leerink Partnrs raised their Q3 2025 earnings estimates for shares of Elanco Animal Health in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $0.14 for the quarter, up from their previous estimate of $0.11. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s Q4 2025 earnings at $0.14 EPS and FY2025 earnings at $0.84 EPS.

A number of other brokerages have also recently issued reports on ELAN. Barclays lowered their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Finally, UBS Group decreased their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Elanco Animal Health Trading Up 1.9%

Shares of NYSE ELAN opened at $13.06 on Monday. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $18.80. The stock has a market cap of $6.49 billion, a P/E ratio of 32.65, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The firm has a 50-day moving average of $9.97 and a 200 day moving average of $11.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the company posted $0.34 EPS. Elanco Animal Health’s revenue was down 1.0% on a year-over-year basis.

Institutional Trading of Elanco Animal Health

Large investors have recently made changes to their positions in the stock. Allworth Financial LP grew its stake in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after acquiring an additional 2,090 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the third quarter worth approximately $35,000. CoreCap Advisors LLC bought a new stake in shares of Elanco Animal Health in the fourth quarter worth approximately $29,000. Parallel Advisors LLC grew its stake in shares of Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after acquiring an additional 1,852 shares during the period. Finally, NBC Securities Inc. bought a new stake in shares of Elanco Animal Health in the first quarter worth approximately $40,000. 97.48% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares of the company’s stock, valued at $1,136,881.80. The trade was a 9.86% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.89% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.